There was no reported revenue for the end of the quarter which ended October 31, 2009 this was the same in comparison to the previous year. There were also no cost of sales or gross profit for this time frame. However, operating, selling, general and administrative expenses decreased by $14,125, or 3% in the 2009 first fiscal quarter to $513,791 from $527,916 in 2008. And finally, loss from operations for the quarter ended October 31, 2009 was $513,791, a decrease of $14,125 or 3% from the loss from operations in the same period in 2008 of $527,916 as a result of the aforementioned decrease in operating, sales and administrative expenses.
Best Damn Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move.
Sign Up for our Free Stock Newsletter
Wellstar International, Inc. through its wholly owned subsidiary, Trillennium Medical Imaging, Inc. (Trillennium) is engaged in developing and licensing the use of advanced thermal imaging technology (TMI SYSTEM) in the consumer health care markets worldwide. The TMI Infrared Technology and software is approved by the United States Food and Drug Administration (FDA) as an adjunctive diagnostic screening procedure for early breast cancer detection, differential diagnosis of pain dysfunctions, (such as reflex sympathetic dystrophy, neuromuscular skeletal syndromes and neurological disorders), detection of pressure ulcers, deep tissue injuries, and bed sores, as well as orthopedic applications. Thermal imaging provides information that is specific to the physiological and functional activity in the body.
Sign up for the free Best Damn Penny Stocks newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website
About Best Damn Penny Stocks
Best Damn Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer
